Researchers at Virginia Tech's Fralin Biomedical Research Institute analyzed how 20 adults with obesity half of whom had been taking GLP-1 receptor agonists for at least four weeks reacted to alcoholic drinks compared to participants not on the drugs
Try taking a walk or doing other gentle movements, such as yoga, and see how you feel
What Endocrinologists and Obesity Medicine Specialists Say The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Pharmacotherapy for obesity should be considered an adjunct to comprehensive lifestyle intervention, not a replacement for it." The full guideline is accessible through the Endocrine Society's journal
The main difference between semaglutide and tirzepatide is that the latter mimics two gut hormones not just one GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)
We recommend increasing your protein intake
Lowering prices might encourage more people who might benefit from these medications to start using them. Recently, the IIFH brought together leading scientists, industry innovators and health care experts to examine how GLP-1-based therapies are transforming obesity and diabetes care
